董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ian McDonald | 男 | President, Chief Executive Officer and Director | 36 | 43.55万美元 | 91.37 | 2023-12-29 |
| Nils Christian Bottler | 男 | Director | 36 | 0.53万美元 | 4.64 | 2023-12-29 |
| Jeremy Fryzuk | 男 | Director | 38 | 0.53万美元 | 6.64 | 2023-12-29 |
| Jan Pedersen | 男 | Director and Chief Science Officer | 59 | 55.62万美元 | 未持股 | 2023-12-29 |
| David Weiner | 男 | Director | 59 | 1.53万美元 | 未持股 | 2023-12-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ian McDonald | 男 | President, Chief Executive Officer and Director | 36 | 43.55万美元 | 91.37 | 2023-12-29 |
| Ryan Cheung | 男 | Chief Financial Officer | 45 | 8.35万美元 | 2.50 | 2023-12-29 |
| Jan Pedersen | 男 | Director and Chief Science Officer | 59 | 55.62万美元 | 未持股 | 2023-12-29 |
| Mark A. Smith | 男 | Chief Medical Officer | 67 | 31.36万美元 | 未持股 | 2023-12-29 |
董事简历
中英对照 | 中文 | 英文- Ian McDonald
-
Ian McDonald是一名企业家和前投资银行家。在加入公司之前，McDonald先生曾在一家TSX上市的金矿公司的管理团队任职。在该职位上，McDonald先生制定并实施了与并购和资本市场相关的公司战略，在一年内实现了1.6亿美元的销售额。此前，他曾担任加拿大投资银行的高级职务，以及温哥华、伦敦和多伦多的私人股本。在麦当劳的指导下，客户筹集了数亿美元的资金。McDonald先生曾担任多家多伦多证券交易所、加拿大证券交易所上市公司和私人公司的董事会成员。
Ian McDonald has served as a director of New Abpro since the Biness Combination. Mr. McDonald has also served as the Chief Executive Officer and as a director of Bright Minds Biosciences Inc. since 2017. Previoly, he served on the management team at a TSX listed gold mining company, Avnel Gold, from Augt 2016 to September 2017. In that capacity, Mr. McDonald developed and implemented the corporate strategy as it relates to M&A and capital markets resulting in a $160 million sale within one year. Previoly, he worked in a senior role at a Canadian Investment Bank and in private equity in Vancouver, London and Toronto. Under McDonald's guidance, clients raised hundreds of millions of dollars in capital. Mr. McDonald has served as a member of the Board of Directors of several TSX Venture Exchange, Canadian Securities Exchange listed and private companies. Mr. McDonald has a B.A. in Biness from Arizona State University. - Ian McDonald是一名企业家和前投资银行家。在加入公司之前，McDonald先生曾在一家TSX上市的金矿公司的管理团队任职。在该职位上，McDonald先生制定并实施了与并购和资本市场相关的公司战略，在一年内实现了1.6亿美元的销售额。此前，他曾担任加拿大投资银行的高级职务，以及温哥华、伦敦和多伦多的私人股本。在麦当劳的指导下，客户筹集了数亿美元的资金。McDonald先生曾担任多家多伦多证券交易所、加拿大证券交易所上市公司和私人公司的董事会成员。
- Ian McDonald has served as a director of New Abpro since the Biness Combination. Mr. McDonald has also served as the Chief Executive Officer and as a director of Bright Minds Biosciences Inc. since 2017. Previoly, he served on the management team at a TSX listed gold mining company, Avnel Gold, from Augt 2016 to September 2017. In that capacity, Mr. McDonald developed and implemented the corporate strategy as it relates to M&A and capital markets resulting in a $160 million sale within one year. Previoly, he worked in a senior role at a Canadian Investment Bank and in private equity in Vancouver, London and Toronto. Under McDonald's guidance, clients raised hundreds of millions of dollars in capital. Mr. McDonald has served as a member of the Board of Directors of several TSX Venture Exchange, Canadian Securities Exchange listed and private companies. Mr. McDonald has a B.A. in Biness from Arizona State University.
- Nils Christian Bottler
-
Nils Christian Bottler是一位风险投资家，目前在Think.Health Ventures担任副合伙人。该公司专注于投资数字健康和医疗器械技术领域的早期初创企业。Think.Health凭借知识、经验和广泛的业务网络，为其投资组合提供了超越金融投资的支持。Bottler先生之前的工作经验是在银行业，主要从事并购项目，以及在德国，中国，英国和阿拉伯联合酋长国的许多咨询项目。然后，他转到数字媒体，在柏林的Axel Springer SE分析，开发和执行新的商业模式，然后以高级副总裁RHÖ；N-Innovations和一流连锁医院RHÖ；Nklinikum AG的身份深入德国医疗保健市场。
Nils Christian Bottler,is a venture capitalist currently working at Think.Health Ventures as an associate partner. The company focuses on investment in early-stage start-ups in the fields of digital health and medical device technology. Think.Health supports its portfolio beyond financial investment with knowledge, experience and access to an extensive business network. Mr. Bottler's prior work experience was in the banking industry working mainly on M&A projects as well as on a number of consulting projects in Germany, China, the UK, and the United Arab Emirates. He then moved to digital media and analyzed, developed and executed new business models at the Axel Springer SE in Berlin before taking a deep dive into the German health care market as SVP RHN-Innovations and the premier hospital chain RHNKLINIKUM AG. - Nils Christian Bottler是一位风险投资家，目前在Think.Health Ventures担任副合伙人。该公司专注于投资数字健康和医疗器械技术领域的早期初创企业。Think.Health凭借知识、经验和广泛的业务网络，为其投资组合提供了超越金融投资的支持。Bottler先生之前的工作经验是在银行业，主要从事并购项目，以及在德国，中国，英国和阿拉伯联合酋长国的许多咨询项目。然后，他转到数字媒体，在柏林的Axel Springer SE分析，开发和执行新的商业模式，然后以高级副总裁RHÖ；N-Innovations和一流连锁医院RHÖ；Nklinikum AG的身份深入德国医疗保健市场。
- Nils Christian Bottler,is a venture capitalist currently working at Think.Health Ventures as an associate partner. The company focuses on investment in early-stage start-ups in the fields of digital health and medical device technology. Think.Health supports its portfolio beyond financial investment with knowledge, experience and access to an extensive business network. Mr. Bottler's prior work experience was in the banking industry working mainly on M&A projects as well as on a number of consulting projects in Germany, China, the UK, and the United Arab Emirates. He then moved to digital media and analyzed, developed and executed new business models at the Axel Springer SE in Berlin before taking a deep dive into the German health care market as SVP RHN-Innovations and the premier hospital chain RHNKLINIKUM AG.
- Jeremy Fryzuk
-
Jeremy Fryzuk是一名私人股本投资专业人士，总部设在伦敦。他拥有超过10年的私人股本经验。他的职业生涯始于多伦多BMO Capital Markets的投资银行业务。Fryzuk先生拥有加拿大达尔豪斯大学金融专业的商业学士学位。
Jeremy Fryzuk,is a private equity investment professional based in London. He has over 10 years of experience in private equity. He started his career in investment banking in Toronto with BMO Capital Markets. Mr. Fryzuk holds a Bachelor of Commerce with a major in Finance from Dalhousie University in Canada. - Jeremy Fryzuk是一名私人股本投资专业人士，总部设在伦敦。他拥有超过10年的私人股本经验。他的职业生涯始于多伦多BMO Capital Markets的投资银行业务。Fryzuk先生拥有加拿大达尔豪斯大学金融专业的商业学士学位。
- Jeremy Fryzuk,is a private equity investment professional based in London. He has over 10 years of experience in private equity. He started his career in investment banking in Toronto with BMO Capital Markets. Mr. Fryzuk holds a Bachelor of Commerce with a major in Finance from Dalhousie University in Canada.
- Jan Pedersen
-
Jan Pedersen，董事兼首席科学官Jan Pedersen，博士，理学硕士，是药物发现研究领域的创新和经验丰富的领导者，在神经科学研究管理方面拥有超过25年的专业知识。Pedersen博士的学术兴趣包括神经退行性变、生物信息学、生物物理学和药物发现研发。他是Torleif Science ApS的创始人，Torleif Science ApS是一家旨在提供神经科学创新和新思想的咨询公司。在此之前，Pedersen博士在专门研究脑部疾病的全球制药公司Lundbeck工作了20年，担任的职务越来越多，包括建立其神经退行性疾病/阿尔茨海默病管道，并将研究项目引入临床。Pedersen博士在丹麦技术大学获得化学硕士学位，在巴斯大学获得生物物理学博士学位。
Jan Pedersen,is an innovative and highly experienced leader in drug discovery research, with more than 25 years of expertise in neuroscience research management. Dr. Pedersen's academic interests include neurodegeneration, bioinformatics, biophysics and drug discovery R&D. He is the founder of Torleif Science ApS, a consultancy company aimed at delivering innovation and new ideas in neuroscience. Prior to that, Dr. Pedersen spent 20 years at Lundbeck, a global pharmaceutical company specialized in brain diseases, in positions of increasing responsibility, including building its neurodegeneration/Alzheimer's disease pipeline, and bringing research programs to the clinic. Dr. Pedersen received an MSc in Chemistry from DTU - Technical University of Denmark, and a PhD in biophysics from the University of Bath. - Jan Pedersen，董事兼首席科学官Jan Pedersen，博士，理学硕士，是药物发现研究领域的创新和经验丰富的领导者，在神经科学研究管理方面拥有超过25年的专业知识。Pedersen博士的学术兴趣包括神经退行性变、生物信息学、生物物理学和药物发现研发。他是Torleif Science ApS的创始人，Torleif Science ApS是一家旨在提供神经科学创新和新思想的咨询公司。在此之前，Pedersen博士在专门研究脑部疾病的全球制药公司Lundbeck工作了20年，担任的职务越来越多，包括建立其神经退行性疾病/阿尔茨海默病管道，并将研究项目引入临床。Pedersen博士在丹麦技术大学获得化学硕士学位，在巴斯大学获得生物物理学博士学位。
- Jan Pedersen,is an innovative and highly experienced leader in drug discovery research, with more than 25 years of expertise in neuroscience research management. Dr. Pedersen's academic interests include neurodegeneration, bioinformatics, biophysics and drug discovery R&D. He is the founder of Torleif Science ApS, a consultancy company aimed at delivering innovation and new ideas in neuroscience. Prior to that, Dr. Pedersen spent 20 years at Lundbeck, a global pharmaceutical company specialized in brain diseases, in positions of increasing responsibility, including building its neurodegeneration/Alzheimer's disease pipeline, and bringing research programs to the clinic. Dr. Pedersen received an MSc in Chemistry from DTU - Technical University of Denmark, and a PhD in biophysics from the University of Bath.
- David Weiner
-
David Weiner，在神经、精神和罕见疾病的新疗法的发现和临床开发方面拥有超过25年的经验。他的职业生涯始于ACADIA Pharmaceuticals，在那里他担任了一系列发现研究和临床开发职务，致力于多种中枢神经系统（CNS）疗法，最著名的是匹马万色林，一种5-HT2A受体反向激动剂，被批准用于治疗帕金森病精神病。Weiner博士还曾担任Proteostasis Therapeutics的首席医疗官（CMO）和临时首席执行官（CEO）、aTyr制药的首席营销官和Amathus Therapeutics的首席执行官Lumos Pharma，以及Eleusis的独立董事会成员和高级管理人员，Eleusis是一家专注于迷幻药和新型5-HT2A受体激动剂的治疗开发的公司。他撰写了30多篇科学出版物和专利，并在多个临床和科学顾问委员会任职，其中包括帕金森研究迈克尔·J·福克斯基金会。他获得了医学与生物医学科学学院的医学博士学位，布法罗的SUNY，是美国国立卫生研究院霍华德休斯医学研究所的研究学者，在康奈尔医学中心纪念斯隆凯特林纽约医院接受神经病学培训，并在佛蒙特大学做神经药理学博士后研究。
David Weiner,has over 25 years of experience in the discovery and clinical development of novel therapeutics for neurological, psychiatric and rare diseases. He began his career at ACADIA Pharmaceuticals, where he held a series of discovery research and clinical development roles working on multiple central nervous system (CNS) therapeutics, most notably pimavanserin, a 5-HT2A receptor inverse agonist, which is approved for the treatment of Parkinson's disease psychosis. Dr. Weiner also served as the Chief Medical Officer (CMO) and Interim Chief Executive Officer (CEO) for Proteostasis Therapeutics, CMO at aTyr Pharma and Lumos Pharma, CEO at Amathus Therapeutics, and as an independent board member and senior executive at Eleusis, a company focused on therapeutic development of psychedelics and novel 5-HT2A receptor agonists. He has authored more than 30 scientific publications and patents and serves on multiple clinical and scientific advisory boards, including the Michael J. Fox Foundation for Parkinsons Research. He received his M.D. from the School of Medicine and Biomedical Sciences, SUNY at Buffalo, was a Howard Hughes Medical Institute Research Scholar at the NIH, trained in neurology at New York Hospital, Memorial Sloan Kettering, Cornell Medical Center, and did a post-doctoral fellowship in neuropharmacology at the University of Vermont. - David Weiner，在神经、精神和罕见疾病的新疗法的发现和临床开发方面拥有超过25年的经验。他的职业生涯始于ACADIA Pharmaceuticals，在那里他担任了一系列发现研究和临床开发职务，致力于多种中枢神经系统（CNS）疗法，最著名的是匹马万色林，一种5-HT2A受体反向激动剂，被批准用于治疗帕金森病精神病。Weiner博士还曾担任Proteostasis Therapeutics的首席医疗官（CMO）和临时首席执行官（CEO）、aTyr制药的首席营销官和Amathus Therapeutics的首席执行官Lumos Pharma，以及Eleusis的独立董事会成员和高级管理人员，Eleusis是一家专注于迷幻药和新型5-HT2A受体激动剂的治疗开发的公司。他撰写了30多篇科学出版物和专利，并在多个临床和科学顾问委员会任职，其中包括帕金森研究迈克尔·J·福克斯基金会。他获得了医学与生物医学科学学院的医学博士学位，布法罗的SUNY，是美国国立卫生研究院霍华德休斯医学研究所的研究学者，在康奈尔医学中心纪念斯隆凯特林纽约医院接受神经病学培训，并在佛蒙特大学做神经药理学博士后研究。
- David Weiner,has over 25 years of experience in the discovery and clinical development of novel therapeutics for neurological, psychiatric and rare diseases. He began his career at ACADIA Pharmaceuticals, where he held a series of discovery research and clinical development roles working on multiple central nervous system (CNS) therapeutics, most notably pimavanserin, a 5-HT2A receptor inverse agonist, which is approved for the treatment of Parkinson's disease psychosis. Dr. Weiner also served as the Chief Medical Officer (CMO) and Interim Chief Executive Officer (CEO) for Proteostasis Therapeutics, CMO at aTyr Pharma and Lumos Pharma, CEO at Amathus Therapeutics, and as an independent board member and senior executive at Eleusis, a company focused on therapeutic development of psychedelics and novel 5-HT2A receptor agonists. He has authored more than 30 scientific publications and patents and serves on multiple clinical and scientific advisory boards, including the Michael J. Fox Foundation for Parkinsons Research. He received his M.D. from the School of Medicine and Biomedical Sciences, SUNY at Buffalo, was a Howard Hughes Medical Institute Research Scholar at the NIH, trained in neurology at New York Hospital, Memorial Sloan Kettering, Cornell Medical Center, and did a post-doctoral fellowship in neuropharmacology at the University of Vermont.
高管简历
中英对照 | 中文 | 英文- Ian McDonald
Ian McDonald是一名企业家和前投资银行家。在加入公司之前，McDonald先生曾在一家TSX上市的金矿公司的管理团队任职。在该职位上，McDonald先生制定并实施了与并购和资本市场相关的公司战略，在一年内实现了1.6亿美元的销售额。此前，他曾担任加拿大投资银行的高级职务，以及温哥华、伦敦和多伦多的私人股本。在麦当劳的指导下，客户筹集了数亿美元的资金。McDonald先生曾担任多家多伦多证券交易所、加拿大证券交易所上市公司和私人公司的董事会成员。
Ian McDonald has served as a director of New Abpro since the Biness Combination. Mr. McDonald has also served as the Chief Executive Officer and as a director of Bright Minds Biosciences Inc. since 2017. Previoly, he served on the management team at a TSX listed gold mining company, Avnel Gold, from Augt 2016 to September 2017. In that capacity, Mr. McDonald developed and implemented the corporate strategy as it relates to M&A and capital markets resulting in a $160 million sale within one year. Previoly, he worked in a senior role at a Canadian Investment Bank and in private equity in Vancouver, London and Toronto. Under McDonald's guidance, clients raised hundreds of millions of dollars in capital. Mr. McDonald has served as a member of the Board of Directors of several TSX Venture Exchange, Canadian Securities Exchange listed and private companies. Mr. McDonald has a B.A. in Biness from Arizona State University.- Ian McDonald是一名企业家和前投资银行家。在加入公司之前，McDonald先生曾在一家TSX上市的金矿公司的管理团队任职。在该职位上，McDonald先生制定并实施了与并购和资本市场相关的公司战略，在一年内实现了1.6亿美元的销售额。此前，他曾担任加拿大投资银行的高级职务，以及温哥华、伦敦和多伦多的私人股本。在麦当劳的指导下，客户筹集了数亿美元的资金。McDonald先生曾担任多家多伦多证券交易所、加拿大证券交易所上市公司和私人公司的董事会成员。
- Ian McDonald has served as a director of New Abpro since the Biness Combination. Mr. McDonald has also served as the Chief Executive Officer and as a director of Bright Minds Biosciences Inc. since 2017. Previoly, he served on the management team at a TSX listed gold mining company, Avnel Gold, from Augt 2016 to September 2017. In that capacity, Mr. McDonald developed and implemented the corporate strategy as it relates to M&A and capital markets resulting in a $160 million sale within one year. Previoly, he worked in a senior role at a Canadian Investment Bank and in private equity in Vancouver, London and Toronto. Under McDonald's guidance, clients raised hundreds of millions of dollars in capital. Mr. McDonald has served as a member of the Board of Directors of several TSX Venture Exchange, Canadian Securities Exchange listed and private companies. Mr. McDonald has a B.A. in Biness from Arizona State University.
- Ryan Cheung
Ryan Cheung是不列颠哥伦比亚省温哥华的MCPA Services Inc.（特许专业会计师）的Founder兼管理合伙人，利用他作为初级风险和资源公司前审计师的经验，他担任公共和私人公司的董事兼高级职员或顾问，提供财务报告，税收和战略指导。自2008年1月起，他一直是British Columbia特许专业会计师协会（原为British Columbia特许会计师协会）的积极成员。张先生拥有British Columbia大学的会计文凭和维多利亚大学的国际商务商业学士学位。
Ryan Cheung,is the founder and managing partner of MCPA Services Inc., Chartered Professional Accountants, in Vancouver, B.C. Leveraging his experience as a former auditor of junior venture and resource companies, Mr. Cheung serves as a director and officer or consultant for public and private companies, providing financial reporting, taxation and strategic guidance.He has been an active member of the Chartered Professional Accountants of British Columbia (formerly Institute of Chartered Accountants of British Columbia) since January 2008. Mr. Cheung holds a diploma in accounting from the University of British Columbia and a Bachelor of Commerce in international business from the University of Victoria.- Ryan Cheung是不列颠哥伦比亚省温哥华的MCPA Services Inc.（特许专业会计师）的Founder兼管理合伙人，利用他作为初级风险和资源公司前审计师的经验，他担任公共和私人公司的董事兼高级职员或顾问，提供财务报告，税收和战略指导。自2008年1月起，他一直是British Columbia特许专业会计师协会（原为British Columbia特许会计师协会）的积极成员。张先生拥有British Columbia大学的会计文凭和维多利亚大学的国际商务商业学士学位。
- Ryan Cheung,is the founder and managing partner of MCPA Services Inc., Chartered Professional Accountants, in Vancouver, B.C. Leveraging his experience as a former auditor of junior venture and resource companies, Mr. Cheung serves as a director and officer or consultant for public and private companies, providing financial reporting, taxation and strategic guidance.He has been an active member of the Chartered Professional Accountants of British Columbia (formerly Institute of Chartered Accountants of British Columbia) since January 2008. Mr. Cheung holds a diploma in accounting from the University of British Columbia and a Bachelor of Commerce in international business from the University of Victoria.
- Jan Pedersen
Jan Pedersen，董事兼首席科学官Jan Pedersen，博士，理学硕士，是药物发现研究领域的创新和经验丰富的领导者，在神经科学研究管理方面拥有超过25年的专业知识。Pedersen博士的学术兴趣包括神经退行性变、生物信息学、生物物理学和药物发现研发。他是Torleif Science ApS的创始人，Torleif Science ApS是一家旨在提供神经科学创新和新思想的咨询公司。在此之前，Pedersen博士在专门研究脑部疾病的全球制药公司Lundbeck工作了20年，担任的职务越来越多，包括建立其神经退行性疾病/阿尔茨海默病管道，并将研究项目引入临床。Pedersen博士在丹麦技术大学获得化学硕士学位，在巴斯大学获得生物物理学博士学位。
Jan Pedersen,is an innovative and highly experienced leader in drug discovery research, with more than 25 years of expertise in neuroscience research management. Dr. Pedersen's academic interests include neurodegeneration, bioinformatics, biophysics and drug discovery R&D. He is the founder of Torleif Science ApS, a consultancy company aimed at delivering innovation and new ideas in neuroscience. Prior to that, Dr. Pedersen spent 20 years at Lundbeck, a global pharmaceutical company specialized in brain diseases, in positions of increasing responsibility, including building its neurodegeneration/Alzheimer's disease pipeline, and bringing research programs to the clinic. Dr. Pedersen received an MSc in Chemistry from DTU - Technical University of Denmark, and a PhD in biophysics from the University of Bath.- Jan Pedersen，董事兼首席科学官Jan Pedersen，博士，理学硕士，是药物发现研究领域的创新和经验丰富的领导者，在神经科学研究管理方面拥有超过25年的专业知识。Pedersen博士的学术兴趣包括神经退行性变、生物信息学、生物物理学和药物发现研发。他是Torleif Science ApS的创始人，Torleif Science ApS是一家旨在提供神经科学创新和新思想的咨询公司。在此之前，Pedersen博士在专门研究脑部疾病的全球制药公司Lundbeck工作了20年，担任的职务越来越多，包括建立其神经退行性疾病/阿尔茨海默病管道，并将研究项目引入临床。Pedersen博士在丹麦技术大学获得化学硕士学位，在巴斯大学获得生物物理学博士学位。
- Jan Pedersen,is an innovative and highly experienced leader in drug discovery research, with more than 25 years of expertise in neuroscience research management. Dr. Pedersen's academic interests include neurodegeneration, bioinformatics, biophysics and drug discovery R&D. He is the founder of Torleif Science ApS, a consultancy company aimed at delivering innovation and new ideas in neuroscience. Prior to that, Dr. Pedersen spent 20 years at Lundbeck, a global pharmaceutical company specialized in brain diseases, in positions of increasing responsibility, including building its neurodegeneration/Alzheimer's disease pipeline, and bringing research programs to the clinic. Dr. Pedersen received an MSc in Chemistry from DTU - Technical University of Denmark, and a PhD in biophysics from the University of Bath.
- Mark A. Smith
MarkA.Smith，医学博士，博士，自2016年6月起担任首席医疗官。Smith从2013年11月到2016年6月担任Teva Pharmaceuticals神经精神病学临床主管。他曾担任Shire Pharmaceuticals公司的负责实验医学、全球临床开发和创新的高级董事（从2012年9月到2013年10月），以及AstraZeneca Pharmaceutical Company的负责临床开发的执行董事（从2000年6月到2012年9月）。他曾担任DuPont Pharmaceutical Company（从1996年到2000年）的CNS疾病研究的高级研究员和首席研究科学家，以及the National Institute of Mental Health的生物精神病学和临床神经内分泌学分支（从1987年到1996年）。Smith博士在药物发现和开发以及临床试验设计和执行方面拥有丰富的专业知识，从0期到II期B指导了大约50项临床试验，并在发现和开发大约20种针对抑郁症的研究性新药方面担任项目负责人，焦虑，精神分裂症和其他疾病。Smith博士在耶鲁大学（Yale University）获得分子生物物理学和生物化学理学学士学位和理学硕士学位；在加州大学圣地亚哥分校（University of California，San Diego）获得生理学和药理学硕士学位，并在杜克大学医学中心（Duke University Medical Center）完成住院医师资格。
Mark A. Smith,Prior to joining the Company, Dr. Smith was Chief Medical Officer at VistaGen Therapeutics, where he led the clinical development of drug candidates in the areas of major depression, social anxiety disorder, and depression through all phases of development. Previously, Dr. Smith served as the Clinical Lead for Neuropsychiatry at Teva Pharmaceuticals, where he was accountable for the strategy and clinical development of neuropsychiatric drugs with a focus on schizophrenia, sleep disorders, and agitation. He also held a range of director positions, including as Executive Director of Clinical Development at AstraZeneca Pharmaceutical Company, where he led the development of several novel chemical entities targeting treatment-resistant depression, anxiety, and schizophrenia.Dr. Smith was also Senior Director of Experimental Medicine of Global Clinical Development and Innovation at Shire Pharmaceuticals and Senior Investigator and Principal Research Scientist of CNS Diseases at DuPont Pharmaceuticals. Prior to joining the pharmaceutical industry, he served as a Senior Staff Scientist of the Biological Psychiatry Branch and Senior Staff Fellow of the Clinical Neuroendocrinology Branch at the U.S. National Institute of Mental Health (NIMH).Dr. Smith received his Bachelor's degree and Master of Science from Yale University, his Doctor of Medicine and Doctor of Pilosophy in Physiology and Pharmacology from the University of California, San Diego, and completed his residency in the Department of Psychiatry at Duke University Medical Center. He currently serves on the National Institute of Mental Health Translational Neuropsychopharmacology Task Force.- MarkA.Smith，医学博士，博士，自2016年6月起担任首席医疗官。Smith从2013年11月到2016年6月担任Teva Pharmaceuticals神经精神病学临床主管。他曾担任Shire Pharmaceuticals公司的负责实验医学、全球临床开发和创新的高级董事（从2012年9月到2013年10月），以及AstraZeneca Pharmaceutical Company的负责临床开发的执行董事（从2000年6月到2012年9月）。他曾担任DuPont Pharmaceutical Company（从1996年到2000年）的CNS疾病研究的高级研究员和首席研究科学家，以及the National Institute of Mental Health的生物精神病学和临床神经内分泌学分支（从1987年到1996年）。Smith博士在药物发现和开发以及临床试验设计和执行方面拥有丰富的专业知识，从0期到II期B指导了大约50项临床试验，并在发现和开发大约20种针对抑郁症的研究性新药方面担任项目负责人，焦虑，精神分裂症和其他疾病。Smith博士在耶鲁大学（Yale University）获得分子生物物理学和生物化学理学学士学位和理学硕士学位；在加州大学圣地亚哥分校（University of California，San Diego）获得生理学和药理学硕士学位，并在杜克大学医学中心（Duke University Medical Center）完成住院医师资格。
- Mark A. Smith,Prior to joining the Company, Dr. Smith was Chief Medical Officer at VistaGen Therapeutics, where he led the clinical development of drug candidates in the areas of major depression, social anxiety disorder, and depression through all phases of development. Previously, Dr. Smith served as the Clinical Lead for Neuropsychiatry at Teva Pharmaceuticals, where he was accountable for the strategy and clinical development of neuropsychiatric drugs with a focus on schizophrenia, sleep disorders, and agitation. He also held a range of director positions, including as Executive Director of Clinical Development at AstraZeneca Pharmaceutical Company, where he led the development of several novel chemical entities targeting treatment-resistant depression, anxiety, and schizophrenia.Dr. Smith was also Senior Director of Experimental Medicine of Global Clinical Development and Innovation at Shire Pharmaceuticals and Senior Investigator and Principal Research Scientist of CNS Diseases at DuPont Pharmaceuticals. Prior to joining the pharmaceutical industry, he served as a Senior Staff Scientist of the Biological Psychiatry Branch and Senior Staff Fellow of the Clinical Neuroendocrinology Branch at the U.S. National Institute of Mental Health (NIMH).Dr. Smith received his Bachelor's degree and Master of Science from Yale University, his Doctor of Medicine and Doctor of Pilosophy in Physiology and Pharmacology from the University of California, San Diego, and completed his residency in the Department of Psychiatry at Duke University Medical Center. He currently serves on the National Institute of Mental Health Translational Neuropsychopharmacology Task Force.